Search Results for: CTNNB1

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
Novel PKD1 polycystin 1, transient receptor potential channel interacting
  • VxPx cargo-targeting to cilium
  • VxPx cargo-targeting to cilium
  • Polycystic kidney disease
Novel PKM pyruvate kinase M1/2
  • Neutrophil degranulation
  • Negative Regulation of CDH1 Gene Transcription
  • Pyruvic acid
  • L-Phospholactate
  • 2-Phosphoglycolic Acid
  • 6-(2-fluorobenzyl)-2,4-dimethyl-4,6-dihydro-5H-thieno[2',3':4,5]pyrrolo[2,3-d]pyridazin-5-one
  • 1-[(2,6-difluorophenyl)sulfonyl]-4-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)piperazine
  • 1-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-4-[(4-methoxyphenyl)sulfonyl]piperazine
  • Indoprofen
  • Copper
  • Polydatin
  • Artenimol
Novel PKP2 plakophilin 2
  • Keratinization
  • Formation of the cornified envelope
  • Arrhythmogenic right ventricular cardiomyopathy (ARVC)
Novel PLK1 polo like kinase 1
  • Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal
  • Polo-like kinase mediated events
  • Golgi Cisternae Pericentriolar Stack Reorganization
  • Golgi Cisternae Pericentriolar Stack Reorganization
  • APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
  • Phosphorylation of the APC/C
  • Phosphorylation of Emi1
  • Condensation of Prophase Chromosomes
  • Separation of Sister Chromatids
  • Resolution of Sister Chromatid Cohesion
  • Regulation of PLK1 Activity at G2/M Transition
  • Activation of NIMA Kinases NEK9, NEK6, NEK7
  • Loss of Nlp from mitotic centrosomes
  • Recruitment of mitotic centrosome proteins and complexes
  • Loss of proteins required for interphase microtubule organization from the centrosome
  • Recruitment of NuMA to mitotic centrosomes
  • Anchoring of the basal body to the plasma membrane
  • RHO GTPases Activate Formins
  • Mitotic Prometaphase
  • Mitotic Metaphase/Anaphase Transition
  • Mitotic Telophase/Cytokinesis
  • Cyclin A/B1/B2 associated events during G2/M transition
  • The role of GTSE1 in G2/M progression after G2 checkpoint
  • AURKA Activation by TPX2
  • EML4 and NUDC in mitotic spindle formation
  • Regulation of MITF-M-dependent genes involved in cell cycle and proliferation
  • 3-[3-chloro-5-(5-{[(1S)-1-phenylethyl]amino}isoxazolo[5,4-c]pyridin-3-yl)phenyl]propan-1-ol
  • 3-[3-(3-methyl-6-{[(1S)-1-phenylethyl]amino}-1H-pyrazolo[4,3-c]pyridin-1-yl)phenyl]propanamide
  • 4-(4-METHYLPIPERAZIN-1-YL)-N-[5-(2-THIENYLACETYL)-1,5-DIHYDROPYRROLO[3,4-C]PYRAZOL-3-YL]BENZAMIDE
  • 1-[5-Methyl-2-(trifluoromethyl)furan-3-yl]-3-[5-[2-[[6-(1H-1,2,4-triazol-5-ylamino)pyrimidin-4-yl]amino]ethyl]-1,3-thiazol-2-yl]urea
  • Wortmannin
  • Fostamatinib
  • Volasertib
Novel PPM1A protein phosphatase, Mg2+/Mn2+ dependent 1A
  • Downregulation of SMAD2/3:SMAD4 transcriptional activity
  • Energy dependent regulation of mTOR by LKB1-AMPK
Novel PRKCG protein kinase C gamma
  • Calmodulin induced events
  • Disinhibition of SNARE formation
  • Trafficking of GluR2-containing AMPA receptors
  • G alpha (z) signalling events
  • WNT5A-dependent internalization of FZD4
  • Response to elevated platelet cytosolic Ca2+
  • Tamoxifen
  • Staurosporine
  • Dequalinium
  • Benzoyl peroxide
  • Fostamatinib
  • Spinocerebellar ataxia (SCA); Machado-Joseph disease (SCA3)
Novel PSEN1 presenilin 1
  • Nuclear signaling by ERBB4
  • Degradation of the extracellular matrix
  • Regulated proteolysis of p75NTR
  • NRIF signals cell death from the nucleus
  • Activated NOTCH1 Transmits Signal to the Nucleus
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • NOTCH2 Activation and Transmission of Signal to the Nucleus
  • EPH-ephrin mediated repulsion of cells
  • Neutrophil degranulation
  • NOTCH3 Activation and Transmission of Signal to the Nucleus
  • NOTCH4 Activation and Transmission of Signal to the Nucleus
  • Noncanonical activation of NOTCH3
  • TGFBR3 PTM regulation
  • Alzheimer's disease (AD)
  • Frontotemporal lobar degeneration (FTLD), including: Pick disease of brain; Frontotemporal dementia (FTD); Ubiquitin-positive frontotemporal dementia (UP-FTD); Progressive supranuclear palsy type 1 (PSNP1); Inclusion body myopathy with early-onset paget disease and frontotemporal dementia (IBMPFD); Frontotemporal dementia, chromosome 3-linked (FTD3)
  • Acne inversa; Hidradenitis supprativa
Novel PSEN2 presenilin 2
  • Nuclear signaling by ERBB4
  • Regulated proteolysis of p75NTR
  • NRIF signals cell death from the nucleus
  • Activated NOTCH1 Transmits Signal to the Nucleus
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • NOTCH2 Activation and Transmission of Signal to the Nucleus
  • EPH-ephrin mediated repulsion of cells
  • NOTCH3 Activation and Transmission of Signal to the Nucleus
  • NOTCH4 Activation and Transmission of Signal to the Nucleus
  • Noncanonical activation of NOTCH3
  • TGFBR3 PTM regulation
  • Alzheimer's disease (AD)
Novel PTGS2 prostaglandin-endoperoxide synthase 2
  • Synthesis of 15-eicosatetraenoic acid derivatives
  • Synthesis of Prostaglandins (PG) and Thromboxanes (TX)
  • Interleukin-10 signaling
  • Interleukin-4 and Interleukin-13 signaling
  • Biosynthesis of DHA-derived SPMs
  • Biosynthesis of EPA-derived SPMs
  • Biosynthesis of DPAn-3 SPMs
  • Biosynthesis of electrophilic ω-3 PUFA oxo-derivatives
  • Dihomo-gamma-linolenic acid
  • Icosapent
  • Aminosalicylic acid
  • Mesalazine
  • Acetaminophen
  • Indomethacin
  • Indomethacin
  • Nabumetone
  • Ketorolac
  • Tenoxicam
  • Lenalidomide
  • Celecoxib
  • Tolmetin
  • Rofecoxib
  • Piroxicam
  • Fenoprofen
  • Valdecoxib
  • Diclofenac
  • Sulindac
  • Flurbiprofen
  • Etodolac
  • Mefenamic acid
  • Naproxen
  • Sulfasalazine
  • Phenylbutazone
  • Meloxicam
  • Carprofen
  • Diflunisal
  • Suprofen
  • Salicylic acid
  • Meclofenamic acid
  • Acetylsalicylic acid
  • Bromfenac
  • Oxaprozin
  • Ketoprofen
  • Balsalazide
  • Ibuprofen
  • Lumiracoxib
  • Magnesium salicylate
  • Salsalate
  • Choline magnesium trisalicylate
  • Ginseng
  • Antrafenine
  • Antipyrine
  • Tiaprofenic acid
  • Etoricoxib
  • Flufenamic acid
  • Resveratrol
  • 1-Phenylsulfonamide-3-Trifluoromethyl-5-Parabromophenylpyrazole
  • Prostaglandin G2
  • Niflumic acid
  • Licofelone
  • Nimesulide
  • Cimicoxib
  • Lornoxicam
  • Aceclofenac
  • Nepafenac
  • Parecoxib
  • Pomalidomide
  • Cannabidiol
  • Loxoprofen
  • Dexibuprofen
  • Dexketoprofen
  • Droxicam
  • Tolfenamic acid
  • Firocoxib
  • Morniflumate
  • Propacetamol
  • Talniflumate
  • Phenyl salicylate
  • Trolamine salicylate
  • Menthyl salicylate
  • Glycol salicylate
  • Dipyrithione
  • Bryostatin 1
  • Alclofenac
  • Bufexamac
  • Bendazac
  • Acemetacin
  • Fish oil
  • Medical Cannabis
  • Nabiximols
  • Esophageal cancer
  • Penile cancer
  • Cholangiocarcinoma
Novel PTPN1 protein tyrosine phosphatase non-receptor type 1
  • Integrin signaling
  • Negative regulation of MET activity
  • Insulin receptor recycling
  • Regulation of IFNG signaling
  • PTK6 Down-Regulation
  • MECP2 regulates neuronal receptors and channels
  • Regulation of IFNA/IFNB signaling
  • Growth hormone receptor signaling
  • Growth hormone receptor signaling
  • Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells
  • 3-(Oxalyl-Amino)-Naphthalene-2-Carboxylic Acid
  • 2-{[4-(2-Acetylamino-2-pentylcarbamoyl-ethyl)-naphthalen-1-YL]-oxalyl-amino}-benzoic acid
  • 5-(2-Fluoro-5-{(1E)-3-[3-hydroxy-2-(methoxycarbonyl)phenoxy]-1-propen-1-yl}phenyl)-1,2-oxazole-3-carboxylic acid
  • 2-(Oxalyl-Amino)-4,7-Dihydro-5h-Thieno[2,3-C]Thiopyran-3-Carboxylic Acid
  • 3-(3,5-Dibromo-4-Hydroxy-Benzoyl)-2-Ethyl-Benzofuran-6-Sulfonic Acid (4-Sulfamoyl-Phenyl)-Amide
  • [[4-(Aminomethyl)Phenyl]Amino]Oxo-Acetic Acid,
  • {4-[(2S)-2-({[(1S)-1-Carboxy-2-phenylethyl]carbamoyl}amino)-3-oxo-3-(pentylamino)propyl]phenoxy}malonic acid
  • Compound 19
  • 3-(4-{2-[2-(2-bromo-acetylamino)-ethyldisulfanyl]-ethylcarbamoyl}-cyclohexylcarbamoyl)-pyrazine-2-carboxylic acid
  • 2-(Oxalyl-Amino)-Benzoic Acid
  • {[2-(1h-1,2,3-Benzotriazol-1-Yl)-2-(3,4-Difluorophenyl)Propane-1,3-Diyl]Bis[4,1-Phenylene(Difluoromethylene)]}Bis(Phosphonic Acid)
  • Novo Nordisk a/S Compound
  • N-(Bromoacetyl)-beta-alanyl-N-(2-{4-[(carboxycarbonyl)amino]phenyl}ethyl)-L-serinamide
  • 7-(1,1-Dioxo-1h-Benzo[D]Isothiazol-3-Yloxymethyl)-2-(Oxalyl-Amino)-4,7-Dihydro-5h-Thieno[2,3-C]Pyran-3-Carboxylic Acid
  • PNU177836
  • 2-(Oxalyl-Amino)-4,7-Dihydro-5h-Thieno[2,3-C]Pyran-3-Carboxylic Acid
  • {[7-(Difluoro-Phosphono-Methyl)-Naphthalen-2-Yl]-Difluoro-Methyl}-Phosphonic Acid
  • 3-(3,5-Dibromo-4-Hydroxy-Benzoyl)-2-Ethyl-Benzofuran-6-Sulfonic Acid [4-(Thiazol-2-Ylsulfamoyl)-Phenyl]-Amide
  • (4S)-5-[[(2S)-1-[[(2S)-1-Amino-3-[4-[difluoro(phosphono)methyl]phenyl]-1-oxopropan-2-yl]amino]-3-[4-[difluoro(phosphono)methyl]phenyl]-1-oxopropan-2-yl]amino]-4-benzamido-5-oxopentanoic acid
  • 4-[[(2S)-1-[[6-[(1-Amino-1-oxo-3-sulfanylpropan-2-yl)amino]-6-oxohexyl]amino]-3-[4-[difluoro(phosphono)methyl]phenyl]-1-oxopropan-2-yl]amino]-3-[[2-[4-[difluoro(phosphono)methyl]phenyl]acetyl]amino]-4-oxobutanoic acid
  • L-cysteic acid
  • 2-(Oxalyl-Amino)-4,5,6,7-Tetrahydro-Thieno[2,3-C]Pyridine-3-Carboxylic Acid
  • -Carbonyl]-Amino}-Butyric Acid
  • Compound 5, 2-(Naphthalen-1-Yl-Oxalyl-Amino)-Benzoicacid
  • 6-(Oxalyl-Amino)-1h-Indole-5-Carboxylic Acid
  • 2-[{4-[(2S)-2-{[(Allyloxy)carbonyl]amino}-3-({4-[3-hydroxy-2-(methoxycarbonyl)phenoxy]butyl}amino)-3-oxopropyl]phenyl}(carboxycarbonyl)amino]benzoic acid
  • 3-(3,5-Dibromo-4-Hydroxy-Benzoyl)-2-Ethyl-Benzofuran-6-Sulfonic Acid Dimethylamide
  • [(4-{4-[4-(Difluoro-Phosphono-Methyl)-Phenyl]-Butyl}-Phenyl)-Difluoro-Methyl]-Phosphonic Acid
  • {4-[(2s,4e)-2-(1,3-Benzothiazol-2-Yl)-2-(1h-1,2,3-Benzotriazol-1-Yl)-5-Phenylpent-4-Enyl]Phenyl}(Difluoro)Methylphosphonic Acid
  • N-(3-Carboxypropanoyl)-L-phenylalanyl-3-carboxy-O-(carboxymethyl)-N-pentyl-L-tyrosinamide
  • 1-METHYL-3-PHENYL-1H-PYRAZOL-5-YLSULFAMIC ACID
  • ISIS 113715
  • Trodusquemine
  • Ertiprotafib
  • 4-BROMO-3-(CARBOXYMETHOXY)-5-[3-(CYCLOHEXYLAMINO)PHENYL]THIOPHENE-2-CARBOXYLIC ACID
  • [(3S)-3-(Methylcarbamoyl)-2-{[(2-methyl-2-propanyl)oxy]carbonyl}-1,2,3,4-tetrahydro-7-isoquinolinyl]sulfamic acid
  • 4-BROMO-3-(CARBOXYMETHOXY)-5-PHENYLTHIOPHENE-2-CARBOXYLIC ACID
  • 5-(4-CHLORO-5-PHENYL-3-THIENYL)-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE
  • 4-BROMO-3-(CARBOXYMETHOXY)-5-(4-HYDROXYPHENYL)THIOPHENE-2-CARBOXYLIC ACID
  • [{2-bromo-4-[(2R)-3-oxo-2,3-diphenylpropyl]phenyl}(difluoro)methyl]phosphonic acid
  • 5-[3-(BENZYLAMINO)PHENYL]-4-BROMO-3-(CARBOXYMETHOXY)THIOPHENE-2-CARBOXYLIC ACID
  • 2-[(7-HYDROXY-NAPHTHALEN-1-YL)-OXALYL-AMINO]-BENZOIC ACID
  • 3-(CARBOXYMETHOXY)THIENO[2,3-B]PYRIDINE-2-CARBOXYLIC ACID
  • 4-PHOSPHONOOXY-PHENYL-METHYL-[4-PHOSPHONOOXY]BENZEN
  • N-ACETYL-L-PHENYLALANYL-4-[DIFLUORO(PHOSPHONO)METHYL]-L-PHENYLALANINAMIDE
  • [(3R)-3-(Methylcarbamoyl)-2-{[(2-methyl-2-propanyl)oxy]carbonyl}-1,2,3,4-tetrahydro-7-isoquinolinyl]sulfamic acid
  • 5-(3-HYDROXYPHENYL)ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDE
  • 5-(3-{3-[3-HYDROXY-2-(METHOXYCARBONYL)PHENOXY]PROPENYL}PHENYL)-4-(HYDROXYMETHYL)ISOXAZOLE-3-CARBOXYLIC ACID
  • ISOTHIAZOLIDINONE ANALOG
  • 4-[3-(dibenzylamino)phenyl]-2,4-dioxobutanoic acid
  • p-Benzoyl-L-phenylalanine
  • 6-(DIFLUORO-PHOSPHONO-METHYL)-NAPHTHALENE-2-CARBOXYLIC ACID
  • (3R)-METHYLCARBAMOYL-7-SULFOAMINO-3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBOXYLIC ACID BENZYL ESTER
  • 5-(4-METHOXYBIPHENYL-3-YL)-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE
  • 1,2,5-THIADIAZOLIDIN-3-ONE-1,1-DIOXIDE
  • (4-{(2S)-2-[(tert-butoxycarbonyl)amino]-3-methoxy-3-oxopropyl}phenyl)methaneseleninic acid
Novel PTPN13 protein tyrosine phosphatase non-receptor type 13
  • Synthesis of PIPs at the plasma membrane
  • Interleukin-37 signaling
  • RND3 GTPase cycle
  • RND2 GTPase cycle
  • RND1 GTPase cycle
Novel PTPN14 protein tyrosine phosphatase non-receptor type 14
  • Interleukin-37 signaling
  • Choanal atresia and lymphedema
Novel PTPN6 protein tyrosine phosphatase non-receptor type 6
  • GPVI-mediated activation cascade
  • Regulation of KIT signaling
  • Signaling by ALK
  • PECAM1 interactions
  • Co-inhibition by PD-1
  • Signal regulatory protein family interactions
  • Platelet sensitization by LDL
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • CD22 mediated BCR regulation
  • Neutrophil degranulation
  • Interferon gamma signaling
  • Regulation of IFNG signaling
  • Interleukin-37 signaling
  • Interferon alpha/beta signaling
  • Interleukin receptor SHC signaling
  • Regulation of IFNA/IFNB signaling
  • SARS-CoV-2 activates/modulates innate and adaptive immune responses
  • Nuclear events stimulated by ALK signaling in cancer
  • Growth hormone receptor signaling
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Co-inhibition by BTLA
  • Tiludronic acid
Novel PTPRB protein tyrosine phosphatase receptor type B
  • Neutrophil degranulation
  • {4-[2-BENZYL-3-METHOXY-2-(METHOXYCARBONYL)-3-OXOPROPYL]PHENYL}SULFAMIC ACID
  • (4-{4-[(TERT-BUTOXYCARBONYL)AMINO]-2,2-BIS(ETHOXYCARBONYL)BUTYL}PHENYL)SULFAMIC ACID
  • {4-[2,2-BIS(5-METHYL-1,2,4-OXADIAZOL-3-YL)-3-PHENYLPROPYL]PHENYL}SULFAMIC ACID
  • (4-ETHYLPHENYL)SULFAMIC ACID
  • Razuprotafib
Novel PTPRF protein tyrosine phosphatase receptor type F
  • Receptor-type tyrosine-protein phosphatases
  • Insulin receptor recycling
  • Synaptic adhesion-like molecules
Novel PTPRJ protein tyrosine phosphatase receptor type J
  • Phosphorylation of CD3 and TCR zeta chains
  • Neutrophil degranulation
  • Negative regulation of MET activity
  • Negative regulation of FLT3
Novel PTPRK protein tyrosine phosphatase receptor type K
  • EGFR downregulation
Novel PTPRM protein tyrosine phosphatase receptor type M
Novel PTPRU protein tyrosine phosphatase receptor type U
  • Signaling by SCF-KIT
Novel PTPRZ1 protein tyrosine phosphatase receptor type Z1
  • Other interleukin signaling
  • MDK and PTN in ALK signaling

Page 8 out of 22 pages